Summary
- Current Price
- As of today, BIIB price is $221.56, up +4.24% on
- Current Price All-Time High
- BIIB price is currently -53.86% below its historical high of $480.18 set on
- Market Cap
- BIIB current market cap is $33B, up +60.81% over the past 365 days
- PE Ratio
- BIIB current PE ratio is 39.24
- Revenue
- BIIB current annual revenue is $9.53B, up +2.88% year-over-year
- Next Earnings
- The next earnings release for BIIB is on
Profile
| Metric | Value |
|---|---|
| Full Name | Biogen Inc. |
| Ticker | NASDAQ: BIIB |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | General Drug Manufacturers |
| Country | United States |
| IPO | |
| Indexes | |
| Website | biogen.com |
| Employees | 7,605 |
Key Metrics
| Metric | Value | Date |
|---|---|---|
| Price | $221.56 | |
| Price, 1D Change | +4.24% | |
| Market Cap | $33B | |
| - | ||
| PE Ratio | 39.24 | |
| Beta | 0.25 | |
| Revenue | $9.53B | |
| Revenue, 1Y Change | +2.88% | |
| EPS | $8.79 | |
| EPS, 1Y Change | -21.43% |
Chart
SUGGESTED SERIES
Events
| Metric | Value | Date |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 3:1 | |
| Next Split | N/A | N/A |
| Last Ticker Change | IDPH | |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Value | Date |
|---|---|---|
| EPS | $8.79 | |
| EPS Estimate | $12.44 | N/A |
| EPS Est. Change | +41.55% | N/A |
| Revenue | $9.53B | |
| Revenue Estimate | $10.43B | N/A |
| Revenue Est. Change | +9.43% | N/A |
| Current Price | $221.56 | |
| Price Target | $237.00 | - |
| Price Tgt. Change | +6.97% | - |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $16.37 | $11.19 | -31.68% | |
| $15.02 | $8.79 | -41.50% | |
| $12.44 | N/A | +41.55% | |
| $16.60 | N/A | +88.90% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $9.64B | $9.27B | -3.87% | |
| $9.83B | $9.53B | -2.99% | |
| $10.43B | N/A | +9.43% | |
| $10.64B | N/A | +11.56% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Value | Date |
|---|---|---|
| Price, 1Y | +59.56% | |
| Price, 3Y | -15.16% | |
| Market Cap, 1Y | +60.81% | |
| Market Cap, 3Y | -13.43% | |
| Revenue, 1Y | +2.88% | |
| Revenue, 3Y | +1.06% | |
| EPS, 1Y | -21.43% | |
| EPS, 3Y | -57.88% |
🔒 Log In To Unlock Full Data
Technicals
| Metric | Value | Date |
|---|---|---|
| Current Price | $221.56 | |
| SMA 200 | $187.36 | |
| SMA 50 | $204.52 | |
| EMA 200 | $187.23 | |
| EMA 50 | $203.98 | |
| MACD | $2.97 | |
| Beta | 0.25 | |
| ATR | $6.53 | |
| 14-Day RSI | 65.67 | |
| 10-Day Volatility | 26.84% |
Dividends
| Metric | Value | Date |
|---|---|---|
| - | N/A | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Value | Date |
|---|---|---|
| Revenue | $9.53B | |
| EPS | $8.79 | |
| Gross Profit | $7.49B | |
| Gross Margin | 75.69% | |
| Operating Income | $2.76B | |
| Operating Margin | 27.90% | |
| Net Income | $1.29B | |
| Net Margin | 13.07% | |
| EBITDA | $3.19B |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Value | Date |
|---|---|---|
| Debt To Equity | 0.36 | |
| 2.68 | ||
| 2.03 | ||
| - | ||
| 4 | ||
| 3.60 |
Valuations
| Metric | Value | Date |
|---|---|---|
| PE Ratio | 39.24 | |
| 3.39 | ||
| 1.74 | ||
| 14.60 | ||
| - | N/A |
Balance Sheet
| Metric | Value | Date |
|---|---|---|
| Book Value | $18.26B | |
| $3.82B | ||
| $29.44B | ||
| $8.97B | ||
| $11.18B | ||
| $3.35B | ||
| Total Debt | $6.66B | |
| $80.40M | ||
| $432.00M |
Expenses
| Metric | Value | Date |
|---|---|---|
| $8.60B | ||
| $4.73B | ||
| $3.08B | ||
| $2.43B | ||
| $779.90M | ||
| $0.00 | ||
| $263.60M |
Cash Flow
| Metric | Value | Date |
|---|---|---|
| $2.20B | ||
| -$1.37B | ||
| -$301.90M | ||
| Capex | $235.40M | |
| $1.97B |
Recent analyst updates
| Metric | Value | Date |
|---|---|---|
| Wolfe Research | → | |
| Mizuho | → | |
| Citigroup | → | |
| Wedbush | → | |
| UBS | → | |
| TD Cowen | → | |
| RBC Capital | → | |
| Morgan Stanley | → | |
| HC Wainwright & Co. | → | |
| Canaccord Genuity | → |
Analyst sentiment
Institutional ownership
Screeners with BIIB
FAQ
- What is the ticker symbol for Biogen Inc.?
- The ticker symbol for Biogen Inc. is NASDAQ:BIIB
- Does Biogen Inc. pay dividends?
- No, Biogen Inc. does not pay dividends
- What sector is Biogen Inc. in?
- Biogen Inc. is in the Healthcare sector
- What industry is Biogen Inc. in?
- Biogen Inc. is in the General Drug Manufacturers industry
- What country is Biogen Inc. based in?
- Biogen Inc. is headquartered in United States
- When did Biogen Inc. go public?
- Biogen Inc. initial public offering (IPO) was on September 17, 1991
- Is Biogen Inc. in the S&P 500?
- Yes, Biogen Inc. is included in the S&P 500 index
- Is Biogen Inc. in the NASDAQ 100?
- No, Biogen Inc. is not included in the NASDAQ 100 index
- Is Biogen Inc. in the Dow Jones?
- No, Biogen Inc. is not included in the Dow Jones index
- When was Biogen Inc. last earnings report?
- Biogen Inc.'s most recent earnings report was on July 29, 2026
- When does Biogen Inc. report earnings?
- The next expected earnings date for Biogen Inc. is October 29, 2026
Data Sources & References
- BIIB Official Website www.biogen.com
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/875045/000087504526000013/0000875045-26-000013-index.htm
- List of S&P 500 Companies www.spglobal.com/spdji/en/indices/equity/sp-500/#overview
- BIIB Profile on Yahoo Finance finance.yahoo.com/quote/BIIB
- BIIB Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/biib
